.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cerilliant
Cipla
Accenture
Johnson and Johnson
Moodys
Daiichi Sankyo
Queensland Health
AstraZeneca
Colorcon

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075371

« Back to Dashboard

NDA 075371 describes DACARBAZINE, which is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hospira, Teva Pharms Usa, and West-ward Pharms Int, and is included in six NDAs. It is available from three suppliers. Additional details are available on the DACARBAZINE profile page.

The generic ingredient in DACARBAZINE is dacarbazine. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dacarbazine profile page.

Summary for 075371

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 075371

Mechanism of ActionAlkylating Activity

Medical Subject Heading (MeSH) Categories for 075371

Suppliers and Packaging for NDA: 075371

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DACARBAZINE dacarbazine INJECTABLE;INJECTION 075371 ANDA APP Pharmaceuticals, LLC 63323-127 63323-127-10 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-127-10) > 10 mL in 1 VIAL, SINGLE-DOSE
DACARBAZINE dacarbazine INJECTABLE;INJECTION 075371 ANDA APP Pharmaceuticals, LLC 63323-128 63323-128-20 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-128-20) > 20 mL in 1 VIAL, SINGLE-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100MG/VIAL
Approval Date:Aug 27, 1999TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength200MG/VIAL
Approval Date:Aug 27, 1999TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Covington
Queensland Health
Chinese Patent Office
Baxter
Merck
Healthtrust
Argus Health
Harvard Business School
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot